HC Wainwright keeps Pyxis Oncology at Buy with $8 price target
HC Wainwright & Co. maintained its Buy rating on Pyxis Oncology and kept its $8 price target, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at HC Wainwright & Co. kept their Buy rating on Pyxis Oncology shares and left their price target unchanged at $8. The update was reported by TradingView, which cites Benzinga data.
The target implies potential upside of 376.2% from the November 19 close of $1.68.
why it matters
With the stock near $1.68, the gap between the current price and the target is very large, so such estimates are worth weighing against the company's financial position and the progress of its clinical programs. This is one brokerage's view, not a broader market trend.
tags
instruments
sources
- HC Wainwright & Co. maintains Pyxis Oncology at Buy, keeps price target at $8 — TradingView, 20 November 2026 at 11:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗